Zai Lab Revenue 2016-2021 | ZLAB

Zai Lab annual/quarterly revenue history and growth rate from 2016 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Zai Lab revenue for the quarter ending September 30, 2021 was $0.043B, a 194.2% increase year-over-year.
  • Zai Lab revenue for the twelve months ending September 30, 2021 was $0.115B, a 403.89% increase year-over-year.
  • Zai Lab annual revenue for 2020 was $0.049B, a 277.04% increase from 2019.
  • Zai Lab annual revenue for 2019 was $0.013B, a 9965.89% increase from 2018.
  • Zai Lab annual revenue for 2018 was $0B, a INF% increase from 2017.
Zai Lab Annual Revenue
(Millions of US $)
2020 $49
2019 $13
2018 $0
2017 $
2016 $
2015 $
Zai Lab Quarterly Revenue
(Millions of US $)
2021-09-30 $43
2021-06-30 $37
2021-03-31 $20
2020-12-31 $15
2020-09-30 $15
2020-06-30
2020-03-31 $8
2019-12-31
2019-09-30
2019-06-30
2018-12-31
2017-12-31
2017-06-30
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.033B $0.049B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00